DocWire News Editors

DocwireNews

Patients transitioning to end-stage renal disease (ESRD) by way of an acute kidney injury requiring dialysis (AKI-D) have a higher risk for death and heart failure hospitalization when compared to patients starting chronic dialysis without AKI-D, new study results suggest.Benjamin J. Lee, MD, and colleagues conducted a retrospective cohort study to test the hypothesis that after controlling for known vascular risk factors, patients with incident ESRD due to AKI-D are at higher short-term risk for death and cardiovascular disease compared with patients with ESRD not attributable to AKI-D. Results of the <a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-018-0924-3">study</a> were reported online in BMC Nephrology.The researchers utilized data from Kaiser Permanente Northern California (KPNC), a large, integrated healthcare delivery system providing inpatient and outpatient care for &gt;4.1 million members in the San Francisco Bay area. All adult (&ge;18 years of age) KPNC members who developed AKI-D or who initiated chronic hemodialysis between January 2009 and September 2015 were identified. Eligible participants had &ge;12 consecutive months of membership in the health plan as well as pharmacy benefits prior to RRT initiation. AKI-D was defined as receipt of RRT during hospitalization in the absence of any preadmission RRT (dialysis or transplant). Inpatient RRT included receipt of peritoneal dialysis, hemodialysis, or hemofiltration.The two primary comparisons were (1) between patients with incident ESRD due to nonrecovery from AKI-D versus incident ESRD patients who did not have AKI-D and (2) between AKI-D patients who did recover kidney function versus those who did not recover adequate kidney function to discontinue dialysis. Recovery from AKI-D was defined as being alive and no longer requiring RRT for &ge;4 weeks at 90 days following acute RRT initiation.The researchers initially identified 13,213 hospitalized patients who received inpatient RRT and 6414 patients who initiated chronic hemodialysis as outpatients between January 2009 and September 2015. After applying inclusion and exclusion criteria, the final sample included 1865 patients with incident ESRD due to AKI-D, 3772 with incident ESRD not due to AKI-D, and 1347 AKI-D patients who recovered within 90 days following initiation of RRT.Compared with the cohort with incident ESRD without AKI-D, those with AKI-D were older, more likely to be white, and had a higher burden of baseline cardiovascular disease. Compared with AKI-D patients who did not recover, those who did recover were younger, more likely to be white, had higher baseline estimated glomerular filtration rate (eGFR), and less likely to have pre-existing heart failure and other cardiovascular disease, hypertension, diabetes, or dyslipidemia.Patients with incident ESRD due to AKI-D had higher all-cause death rates in unadjusted analyses compared with patients with incident ESRD who did not experience AKI-D. Crude rates of hospitalization for heart failure and acute coronary syndrome (ACS) were significantly higher in patients with incident ESRD due to AKI-D than in patients with ESRD without AKI-D; there were no significant difference in rates of stroke/transient ischemic attack (TIA).In multivariable analyses, compared with patients with incident ESRD due to AKI-D, those with incident ESRD not due to AKI-D had a significantly lower adjusted rate of all-cause death (adjusted hazard ratio [aHR], 0.56; 95% confidence interval [CI], 0.47-0.67). Following further adjustment for potential confounders, there was also an association between ESRD not due to AKI-D and a lower adjusted rate of hospitalization for heart failure (aHR, 0.45; 95% CI, 0.30-0.70). There was no association between ESRD not due to AKI-D and lower adjusted rate of ACS or stroke/TIA.In sensitivity analyses that excluded AKI-D patients with pre-existing eGFR &le;24 mL/min/1.73 m2, crude and adjusted results for death and hospitalization for heart failure were similar (aHR, 0.43; 95% CI, 0.28-0.67 and aHR, 0.61; 95% C I, 0.27-1.37, respectively).Crude rates of all-cause death, ACS, and stroke/TIA were lower in patients who recovered from AKI-D compared with those who did not recover. In multivariable analyses, there was an independent association between recovery from AKI-D and lower mortality (aHR, 0.70; 95% CI, 0.55-0.88) compared with non-recovery. There were no significant adjusted differences in rates of <a href="https://proddocwire.wpengine.com/conference-coverage/pioneer-hf-sacubitril-valsartan-stabilizes/">heart failure</a>, ACS, or stroke/TIA. In sensitivity analyses, both crude and adjusted results were similar (aHR for death, 0.59; 95% CI, 0.44-0.80).The researchers did cite some limitations to the study, including possible misclassification of patients with AKI-D who initiated dialysis due to progression of advanced CKD rather than true AKI, lack of details on inpatient dialysis prescriptions (modality, dose, or use of anticoagulation) or etiology of AKI-D, and limiting the study population to insured patients from Northern California.&ldquo;We found that patients who transition to ESRD via AKI-D are at higher risk for short-term death and heart failure hospitalization compared with those who start chronic dialysis without experiencing AKI-D. Our findings indicate that the high short-term mortality in incident ESRD patients may be explained, at least in part, by the subset of patients who developed ESRD via AKI-D. Furthermore, our findings suggest that this subset of incident ESRD patients may have worse outcomes because of pre-existing heart failure. Recovery from AKI-D was also independently associated with lower short-term mortality. Collectively, these findings suggest that aggressive surveillance for and medical management of heart failure in ESRD patients may be a potential strategy for reducing early mortality after AKI-D. Further studies are warranted to evaluate whether promotion of renal recovery from AKI-D and systematic surveillance and intervention for heart failure can improve outcomes in this vulnerable patient population,&rdquo; the researchers said.This article was edited from an original article <a href="http://nephtimes.com/mortality-cardiovascular-risk-aki-requiring-dialysis/?oc_slh=5b89dc40f092c44162a9f21418b5f251c1bc8cb0f79acb9827c59fea3ad485cf&amp;articleclck=yes&amp;usr=5">cross-posted</a> at Nephrology Times.

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

Mortality and Cardiovascular Risk after Acute Kidney Injury

Acute Kidney Injury

Patients transitioning to end-stage renal disease (ESRD) by way of an acute kidney injury requiring dialysis (AKI-D) have a higher risk for death and heart failure ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe